Global Information
회사소개 | 문의 | 비교리스트

세계의 암치료용 모노클로널 항체 시장(2017-2021년)

Global Cancer Monoclonal Antibodies Market 2017-2021

리서치사 TechNavio (Infiniti Research Ltd.)
발행일 2016년 12월 상품 코드 410525
페이지 정보 영문 115 Pages
가격
US $ 2,500 ₩ 3,041,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 ₩ 3,649,000 PDF by E-mail (5-user license) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,866,000 PDF by E-mail (Enterprise License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 6,083,000 PDF by E-mail (Global license) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다. 또한 해당 라이선스는 보고서 컨텐츠의 15% 이내로 외부용 문서에 인용 게재가 허용됩니다(예:프레스릴리스, 마케팅 자료, 백서 등).


세계의 암치료용 모노클로널 항체 시장(2017-2021년) Global Cancer Monoclonal Antibodies Market 2017-2021
발행일 : 2016년 12월 페이지 정보 : 영문 115 Pages

세계의 암치료용 모노클로널 항체(mAb) 시장은 2017-2021년간 CAGR(연평균 성장률)로 10.86%의 성장이 예측됩니다.

세계의 암치료용 모노클로널 항체(mAb) 시장에 대해 조사분석했으며, 시장 규모와 성장률, 시장 동향, 시장 성장 촉진요인·과제, 시장 기회 검증, 주요 벤더 등에 관한 정보를 정리하여 전해드립니다.

제1장 개요

제2장 조사 범위

  • 시장 개요
  • 전제조건
  • 주요 벤더 제품

제3장 시장 조사 방법

  • 조사 방법
  • 경제지표

제4장 서론

  • 주요 시장 하이라이트

제5장 mAb : 개요

  • mAb 치료의 진화
  • mAb를 이용하는 포합형 암치료

제6장 암치료용 mAb의 타임라인

제7장 파이프라인 포트폴리오

  • 제III상 파이프라인 분자
  • 제II상 파이프라인 분자
  • 제I상 파이프라인 분자

제8장 시장 구도

  • 시장 개요
  • Five Forces 분석

제9장 세계의 암치료용 mAb 시장 : mAb 종류별

제10장 세계의 암치료용 mAb 시장 : 작용기서별

제11장 세계의 암치료용 mAb 시장 : 지역별

  • 아메리카
  • 유럽, 중동 및 아프리카
  • 아시아태평양 지역

제12장 세계의 암치료용 mAb 시장 : 촉진요인

제13장 촉진요인의 영향

제14장 세계의 암치료용 mAb 시장 : 과제

제15장 촉진요인과 과제의 영향

제16장 세계의 암치료용 mAb 시장 : 동향

제17장 벤더 구도

  • 경쟁 시나리오
  • 주요 뉴스
  • 기타 유력 벤더

제18장 주요 벤더 분석

  • Amgen
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Takeda Pharmaceuticals

제19장 부록

제20장 Technavio 소개

KSA 17.01.12

About Cancer Monoclonal Antibodies

The mAbs, which are produced by genetic engineering, target antigens in cells, tissues, and organs. They are used in clinical applications to treat diseases with excellent efficacy and minimal side effects. Their MOA, absence of generic pathway, and therapeutic applications distinguish them from other targeted therapeutics.

Technavio's analysts forecast the global cancer monoclonal antibodies market to grow at a CAGR of 10.86% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global cancer monoclonal antibodies market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of branded cancer mAbs and biosimilars used to treat cancer. It also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Cancer Monoclonal Antibodies Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • F. Hoffmann-La Roche
  • Amgen
  • Bristol-Myers Squibb
  • Takeda Pharmaceuticals

Other Prominent Vendors

  • AbbVie
  • ADC Therapeutics
  • Agensys
  • Argos Therapeutics
  • Astellas Pharma
  • AstraZeneca
  • Bayer
  • Biogen
  • Biotech Pharmaceutical
  • BioGenomics
  • Boehringer Ingelheim
  • Celldex Therapeutics
  • Chugai Pharmaceutical
  • CTI BioPharma
  • Daiichi Sankyo
  • Eli Lilly
  • Fortress Biotech
  • Genmab
  • Immunomedics
  • Intas Pharmaceuticals
  • Janssen Biotech
  • Kyowa Hakko Kirin
  • Merck
  • MedImmune
  • Morphotek
  • Neovii Biotech
  • Novartis
  • OncoMed Pharmaceuticals
  • Pfizer
  • Sanofi
  • Seattle Genetics
  • TG Therapeutics
  • Xbiotech

Market driver

  • Increase in demand for ADCs
  • For a full, detailed list, view our report

Market challenge

  • Complicated regulatory framework
  • For a full, detailed list, view our report

Market trend

  • Emergence of targeted and combination therapies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our procurement specialist's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

  • Market overview
  • Assumptions
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: mAbs: Overview

  • Evolution of mAb therapeutics
  • Conjugated cancer therapies using mAbs

PART 06: Timeline of mAbs for cancer

PART 07: Pipeline portfolio

  • List of Phase III pipeline molecules
  • List of Phase II pipeline molecules
  • List of Phase I pipeline molecules

PART 08: Market landscape

  • Market overview
  • Five forces analysis

PART 09: Market segmentation by type of mAbs

  • Naked mAbs
  • Conjugated mAbs

PART 10: Market segmentation by MOA

  • Immune system suppressors
  • Kill or inhibit malignant cells
  • Angiogenesis inhibitors
  • Radiation therapy to cancer cells
  • Delivering chemotherapy to cancer cells

PART 11: Geographical segmentation

  • Cancer mAbs market in Americas
  • Cancer mAbs market in EMEA
  • Cancer mAbs market in APAC

PART 12: Market drivers

  • Increase in demand for ADCs
  • Special regulatory drug designations
  • Advanced technological innovations
  • Increase in industry-academia collaborations

PART 13: Impact of drivers

PART 14: Market challenges

  • Complicated regulatory framework
  • Absence of adequate diagnosis and screening procedures
  • High manufacturing costs coupled with stringent regulations
  • Threat from chemotherapy and off-label drugs

PART 15: Impact of drivers and challenges

PART 16: Market trends

  • Emergence of targeted and combination therapies
  • Joint ventures and partnerships for R&D
  • Advent of biosimilars expected to improve the treatment rates

PART 17: Vendor landscape

  • Competitive scenario
  • Key news
  • Other prominent vendors

PART 18: Key vendor analysis

  • Amgen
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Takeda Pharmaceuticals

PART 19: Appendix

  • List of abbreviations

PART 20: Explore Technavio

List of Exhibits

  • Exhibit 01: Offerings
  • Exhibit 02: Key buying criteria for cancer mAbs 2016
  • Exhibit 03: Impact of key customer segments on the market 2016
  • Exhibit 04: Comparison of small molecule and mAbs
  • Exhibit 05: Preparation of mAbs
  • Exhibit 06: Types of mAbs
  • Exhibit 07: Targeted mechanisms of cancer mAbs
  • Exhibit 08: Timeline of mAbs for cancer
  • Exhibit 09: Global cancer mAbs market: Share of pipeline molecules
  • Exhibit 10: Global cancer mAbs market: Phase III pipeline molecules
  • Exhibit 11: Global cancer mAbs market: Phase II pipeline molecules
  • Exhibit 12: Global cancer mAbs market: Phase I pipeline molecules
  • Exhibit 13: Overview of global cancer mAb market 2016-2021
  • Exhibit 14: Global cancer mAbs market snapshot: Developed and emerging markets 2016
  • Exhibit 15: Global cancer mAbs market 2016-2021 ($ billions)
  • Exhibit 16: A few of patient assistance programs offered by various drugs
  • Exhibit 17: Few awareness programs for various cancers
  • Exhibit 18: Patent expiries of top-selling mAbs by 2021 in US
  • Exhibit 19: Patent expiries of top selling mAbs by 2021 in Europe
  • Exhibit 20: Annual treatment cost per patient for various oncology drugs 2015
  • Exhibit 21: Analysis of global cancer mAbs market by type of application
  • Exhibit 22: Five forces analysis
  • Exhibit 23: Market share of global cancer mAbs market by type of mAbs:
  • Exhibit 24: US FDA- and EU-approved naked cancer mAbs
  • Exhibit 25: Currently available conjugated mAbs
  • Exhibit 26: Market segmentation by MOA
  • Exhibit 27: Global cancer mAbs market revenue by geography 2016-2021 ($ billions)
  • Exhibit 28: Overview of cancer mAbs market in Americas
  • Exhibit 29: Cancer mAbs market in Americas 2016-2021 ($ billions)
  • Exhibit 30: Cancer mAb market in Americas: Opportunity analysis
  • Exhibit 31: Cancer mAbs market in Americas by country 2015
  • Exhibit 32: Cancer mAbs market in US 2016-2021 ($ billions)
  • Exhibit 33: Overview of cancer mAbs market in EMEA
  • Exhibit 34: Cancer mAbs market in EMEA 2016-2021 ($ billions)
  • Exhibit 35: Cancer mAbs market in EMEA by country 2016
  • Exhibit 36: Cancer mAb market in EMEA: Opportunity analysis
  • Exhibit 37: Overview of cancer mAbs market in APAC
  • Exhibit 38: Cancer mAbs market in APAC 2016-2020 ($ billions)
  • Exhibit 39: Cancer mAb market in APAC: Opportunity analysis
  • Exhibit 40: Timeline of ADCs
  • Exhibit 41: ADC molecules under clinical trials
  • Exhibit 42: Special regulatory designations approved by US FDA
  • Exhibit 43: Special regulatory designations approved by EU
  • Exhibit 44: Advances in ADCs technology
  • Exhibit 45: Advances in engineered and bispecific antibodies technology
  • Exhibit 46: Impact of drivers
  • Exhibit 47: Impact of drivers and challenges
  • Exhibit 48: Expected combination regimen launches in oncology
  • Exhibit 49: Market share analysis 2016
  • Exhibit 50: YoY sales comparison of top cancer mAbs 2013-2015 ($ billions)
  • Exhibit 51: Competitive assessment of vendors
  • Exhibit 52: Key vendors: Geographical presence 2015
  • Exhibit 53: Amgen: Key highlights
  • Exhibit 54: Amgen: Strength assessment
  • Exhibit 55: Amgen: Strategy assessment
  • Exhibit 56: Amgen: Opportunity assessment
  • Exhibit 57: Bristol-Myers Squibb: Key highlights
  • Exhibit 58: Bristol-Myers Squibb: Strength assessment
  • Exhibit 59: Bristol-Myers Squibb: Strategy assessment
  • Exhibit 60: Bristol-Myers Squibb: Opportunity assessment
  • Exhibit 61: Hoffmann-La Roche: Key highlights
  • Exhibit 62: F. Hoffmann-La Roche: Strength assessment
  • Exhibit 63: F. Hoffmann-La Roche: Strategy assessment
  • Exhibit 64: F. Hoffmann-La Roche: Opportunity assessment
  • Exhibit 65: Takeda Pharmaceuticals: Highlights
  • Exhibit 66: Takeda Pharmaceuticals: Strength assessment
  • Exhibit 67: Takeda Pharmaceuticals: Strategy assessment
  • Exhibit 68: Takeda Pharmaceuticals: Opportunity assessment
Back to Top
전화 문의
F A Q